• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by COMPASS Pathways Plc

    8/25/23 4:31:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SC 13G 1 ea184249-13gvivo_compass.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.    )*

     

    COMPASS Pathways plc

    (Name of Issuer)

     

    Ordinary Shares, par value £0.008 per share, represented by American Depositary Shares

    (Title of Class of Securities)

     

    20451W101**

    (CUSIP Number)

     

    August 18, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    þRule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **CUSIP number 20451W101 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on The Nasdaq Global Select Market. Each ADS represents one Ordinary Shares of the Issuer.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨         (b)   þ

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

    SOLE VOTING POWER

     

    3,216,000 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    3,216,000 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,216,000 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.1% (2)

    12.

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The number includes (i) 1,608,000 ordinary shares, par value £0.008 per share (the “Ordinary Shares”) of COMPASS Pathways plc (the “Issuer”), which are represented by 1,608,000 American Depository Shares (“ADSs”); and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding Ordinary Shares. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)Based on 61,859,921 Ordinary Shares outstanding of the Issuer, which includes the sum of (i) 45,783,171 Ordinary Shares issued and outstanding of the Issuer as of July 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2023, (ii) 16,076,750 Ordinary Share represented by 16,076,750 ADSs, issued in a private placement transaction that was closed on August 18, 2023, as reported in the Issuer’s Periodic Report on Form 8-K, filed with the SEC on August 16, 2023; and (iii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of warrants held of records by Vivo Opportunity Fund Holdings, L.P.

     

    2

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ¨         (b)   þ

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5.

    SOLE VOTING POWER

     

    3,216,000 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    3,216,000 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,216,000 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.1% (2)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The number includes (i) 1,608,000 Ordinary Shares of the Issuer, which are represented by 1,608,000 ADSs; and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the Issuer’s outstanding Ordinary Shares. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)Based on 61,859,921 Ordinary Shares outstanding of the Issuer, which includes the sum of (i) 45,783,171 Ordinary Shares issued and outstanding of the Issuer as of July 31, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2023, (ii) 16,076,750 Ordinary Share represented by 16,076,750 ADSs, issued in a private placement transaction that was closed on August 18, 2023, as reported in the Issuer’s Periodic Report on Form 8-K, filed with the SEC on August 16, 2023; and (iii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of warrants held of records by Vivo Opportunity Fund Holdings, L.P.

     

    3

     

     

    Item 1. Issuer

     

    (a)Name of Issuer:

     

    COMPASS Pathways plc (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    33 Broadwick Street, London W1F 0DQ, United Kingdom

     

    Item 2. Filing Person

     

    (a) – (c) Name of Persons Filing; Address; Citizenship:

     

    (i)Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership;

     

    (ii)Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.

     

    (d)Title of Class of Securities:

     

    Ordinary Shares, par value £0.008 per share (the “Ordinary Shares”), represented by American Depositary Shares (the “ADSs”)

     

    (e)

    CUSIP Number:

     

    20451W101

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned and (b) percent of class: The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.

     

    4

     

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    Vivo Opportunity Fund Holdings, L.P.: (i) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants

     

    Vivo Opportunity, LLC: (i) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs; and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose of or to direct the disposition of:

     

    Vivo Opportunity Fund Holdings, L.P.: (i) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants

     

    Vivo Opportunity, LLC: (i) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs; and (ii) 1,608,000 Ordinary Shares, represented by 1,608,000 ADSs, issuable upon exercise of certain warrants

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 25, 2023  
       
    Vivo Opportunity Fund Holdings, L.P.  
       
    By: Vivo Opportunity, LLC, its General Partner  
       
    /s/ Hongbo Lu  
    Name: Hongbo Lu  
    Title: Managing Member  
       
    Vivo Opportunity, LLC  
       
    /s/ Hongbo Lu  
    Name:  Hongbo Lu  
    Title: Managing Member  

     

    6

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    99.1   Joint Filing Statement

     

    7

     

    Get the next $CMPS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COMPASS Pathways downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded COMPASS Pathways from Outperform to In-line and set a new price target of $6.00 from $11.00 previously

    6/23/25 9:15:38 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on COMPASS Pathways with a new price target

    Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

    2/27/25 6:17:48 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on COMPASS Pathways with a new price target

    RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

    7/23/24 6:23:14 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CMPS
    SEC Filings

    View All

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 6,366 units of Ordinary Shares, decreasing direct ownership by 3% to 221,302 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    8/4/25 9:31:12 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gover Justin D.

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    7/30/25 4:25:59 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gover Justin D.

    3 - COMPASS Pathways plc (0001816590) (Issuer)

    7/30/25 4:12:03 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Management will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA, with a company presentation scheduled at 4:00pm ET. A broadcast of Compass's presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of this webcast will be accessible for 30 days following the event. For more information, please visit our investor website. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicat

    8/5/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

    Positive primary endpoint achieved in first COMP360 Phase 3 trial with high statistical significance, clinically meaningful reduction in depression at 6 weeks, and no unexpected safety findings Second ongoing pivotal Phase 3 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass exploring options for potential accelerated COMP360 filing for TRD Cash position of $221.9 million at June 30, 2025; cash runway into 2027 Conference call on July 31 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its fina

    7/31/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Appoints Justin Gover to Board of Directors

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Justin Gover to its Board of Directors, effective immediately. Mr. Gover brings more than 25 years of leadership in the biopharmaceutical industry to this role. As part of this Board transition, Dr. Linda McGoldrick will retire from her position on the Board at the end of October after more than 5 years of service. Having helped guide Compass's growth through its 2020 initial public offering and early clinical milestones, Dr. McGoldrick has been a key and invaluable counselor in the company's achievements.

    7/29/25 6:30:00 AM ET
    $CMPS
    $XENE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by COMPASS Pathways Plc

    SCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    8/14/25 5:35:42 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by COMPASS Pathways Plc

    SCHEDULE 13G - COMPASS Pathways plc (0001816590) (Subject)

    8/14/25 4:40:49 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    7/31/25 6:31:16 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Financials

    Live finance-specific insights

    View All

    Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter ended June 30, 2025, and provide an update on recent developments, on July 31, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on July 31, 2025. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:

    7/22/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

    4/28/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

    Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

    2/18/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    View All

    Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

    4/29/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways appoints Lori Englebert as Chief Commercial Officer

    New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

    6/26/24 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways appoints Teri Loxam as Chief Financial Officer

    LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

    12/7/23 7:00:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:35:16 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

    SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

    11/14/24 4:20:24 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by COMPASS Pathways Plc

    SC 13G - COMPASS Pathways plc (0001816590) (Subject)

    4/11/24 4:04:21 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care